Stocks › APVO

Aptevo Therapeutics Inc.

APVO·Nasdaq·United States United States·USD
$0.40
-0.01 (-2.37%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
APVO
Aptevo Therapeutics Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
APVOS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of APVO by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Steve CohenSteve CohenHouse · D · TN APVOAptevo Therapeutics Inc. · Stock Sale
$470.99
Jul 3, 2019 Jun 24, 2019 Filing ↗

Whale Activity

Position changes in APVO reported for 2026-09-30 by 14 institutional filers
New: 5Held: 5Decreased: 1Closed: 3
  • Increased0
  • New5
  • Held5
  • Decreased1
  • Closed3
  • No prior filing0

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by APVO insiders, by quarter · Form 4
-20.0K-10.0K010.0K20.0K2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 13.5K2025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: 02026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

206 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Harsanyi ZsoltDirector Option exercise +400 — — Aug 6, 2026 Form 4 ↗
Lamothe Jeffrey G.President and CEO · Director Option exercise +961 — — Aug 6, 2026 Form 4 ↗
Taylor DaphneSVP, CFO Option exercise +638 — — Aug 6, 2026 Form 4 ↗
Kwon SoYoungSVP, GC, BD & Corp Affairs Option exercise +638 — — Aug 6, 2026 Form 4 ↗
Huebner DirkSVP, CMO Tax withholding −156 $4.07 $635 Aug 6, 2026 Form 4 ↗
Huebner DirkSVP, CMO Option exercise +638 — — Aug 6, 2026 Form 4 ↗
Grant Grady IIIDirector Option exercise +400 — — Aug 6, 2026 Form 4 ↗
White Marvin LExecutive Chair · Director Tax withholding −406 $4.07 $2K Aug 6, 2026 Form 4 ↗
White Marvin LExecutive Chair · Director Option exercise +1,666 — — Aug 6, 2026 Form 4 ↗
Abdun-Nabi DanielDirector Option exercise +400 — — Aug 6, 2026 Form 4 ↗
Kunz Barbara LopezDirector Option exercise +400 — — Aug 6, 2026 Form 4 ↗
Niederhuber JohnDirector Option exercise +400 — — Aug 6, 2026 Form 4 ↗
White Marvin LExecutive Chair · Director Option exercise +1 — — Jul 17, 2026 Form 4 ↗
Grant Grady IIIDirector Purchase +13.5K $1.49 $20K Nov 10, 2025 Form 4 ↗
Harsanyi ZsoltDirector Option exercise +1 — — Jul 17, 2025 Form 4 ↗
Kunz Barbara LopezDirector Option exercise +1 — — Jul 17, 2025 Form 4 ↗
Abdun-Nabi DanielDirector Option exercise +1 — — Jul 17, 2025 Form 4 ↗
Grant Grady IIIDirector Option exercise +1 — — Jul 17, 2025 Form 4 ↗
Niederhuber JohnDirector Option exercise +1 — — Jul 17, 2025 Form 4 ↗
Taylor DaphneSVP, CFO Option exercise +3 — — Jul 17, 2025 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding APVO · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
12.7K$56K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
6,351$15K0.00%Aug 31, 2026
Fidelity Series Total Market Index Fund
Fidelity Concord Street Trust
1,548$4K0.00%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list APVO's shares (CUSIP 03835L702), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Heights Capital Management, Inc.SCHEDULE 13G/A · passive (13G) · 83.9K shares4.4%
    Nov 16, 2026 · ↗
  • CVI Investments, Inc.SCHEDULE 13G/A · passive (13G) · 83.9K shares4.4%
    Nov 16, 2026 · ↗
  • Waqas KhatriSCHEDULE 13G/A · passive (13G) · 70.0K shares3.7%
    Nov 12, 2026 · ↗
  • Alto Opportunity Master Fund, SPC - Segregated Master Portfolio BSCHEDULE 13G/A · passive (13G) · 70.0K shares3.7%
    Nov 12, 2026 · ↗
  • Ayrton Capital LLCSCHEDULE 13G/A · passive (13G) · 70.0K shares3.7%
    Nov 12, 2026 · ↗
  • Heights Capital Management, Inc.SCHEDULE 13G/A · passive (13G) · 83.9K shares6.3%
    Aug 14, 2026 · ↗
  • CVI Investments, Inc.SCHEDULE 13G/A · passive (13G) · 83.9K shares6.3%
    Aug 14, 2026 · ↗
  • NIOWAVE, INC.SCHEDULE 13G · passive (13G) · 151.7K shares12.2%
    Jun 22, 2026 · ↗
  • BANK OF AMERICA CORP /DE/SCHEDULE 13G/A · passive (13G) · 86 shares0.0%
    Nov 7, 2025 · ↗
  • BANK OF AMERICA CORP /DE/SCHEDULE 13G · passive (13G) · 494.3K shares15.0%
    Oct 6, 2025 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Aptevo Therapeutics Inc. as client

No lobbying filings found naming Aptevo Therapeutics Inc. as the client.

Government Contracts

Federal awards to Aptevo Therapeutics Inc. · USAspending

No federal contract awards found for Aptevo Therapeutics Inc..

U.S. Patents

Recent USPTO applications naming Aptevo Therapeutics Inc.

No USPTO patent applications found for Aptevo Therapeutics Inc..

Annual Financials

From APVO's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenuen/an/an/a$3.1M$12.3M
Operating income-$26.3M-$24.6M-$28.9M-$28.6M-$21.4M
Net income-$26.0M-$24.1M-$17.4M$8.0M-$28.5M
Diluted EPS-$87.27-$31460.23-$2316.83$1.57-$6.07
Operating cash flow-$25.6M-$23.8M-$11.7M-$21.0M-$21.7M
Cash and equivalents$21.6M$8.7M$16.9M$22.6M$45.0M
Total assets$27.2M$15.6M$24.8M$34.2M$56.6M
Total liabilities$9.8M$10.8M$12.6M$16.2M$55.4M
Shareholders' equity$17.4M$4.8M$12.2M$18.0M$1.2M

As Aptevo Therapeutics Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-18Reverse splitDec 30, 2025
  • 1-for-20Reverse splitMay 27, 2025
  • 1-for-37Reverse splitDec 4, 2024
  • 1-for-44Reverse splitMar 6, 2024
  • 1-for-14Reverse splitMar 27, 2020

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 16, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 3.02, 8.01, 9.01Material agreement · Unregistered sale of equity · Other eventsNov 12, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsNov 9, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsNov 5, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsNov 2, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsOct 26, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 3.03, 9.01Material agreement · Modification of rightsOct 23, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsOct 14, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsSep 24, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteSep 23, 2026
    EDGAR ↗

About Aptevo Therapeutics Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSEATTLE, WA
IncorporatedDE